Review Finds CBD a ‘Promising’ but Unproven Acne Treatment

Cannabidiol shows genuine biological promise for calming the inflammation and excess oil that drive acne, but the human evidence behind it is still too thin to call it a proven treatment. That is the carefully hedged conclusion of a new systematic review that pooled 13 studies published between 2010 and 2024 on hemp-derived CBD and acne-related outcomes.

The review¹, published in the peer-reviewed journal Molecules, was carried out by Baatile Komane and Thobile Kaye at Tshwane University of Technology in South Africa, with no external funding behind it. The authors registered their protocol in advance and followed PRISMA reporting standards — the kind of methodological discipline that separates a structured evidence synthesis from a marketing claim. Their bottom line: CBD-containing hemp extracts are “promising adjunctive cosmeceuticals for inflammatory acne,” not a frontline therapy.

What the evidence actually shows

The strongest signal sits at the cellular level. Across lab-based and ex vivo studies, CBD consistently dialed down the inflammatory messengers central to acne — including TNF-α and interleukins 1β, 6 and 8 — with reductions of roughly 40 to 70 percent in those models. It did so by acting on the skin’s own endocannabinoid signaling: normalizing the runaway lipid production of sebaceous gland cells and quieting the inflammation triggered by Cutibacterium acnes, the bacterium long tied to acne.

That mechanism is not new. A foundational 2014 study in the Journal of Clinical Investigation first showed that CBD acts as a sebostatic, or oil-suppressing, agent on human sebocytes — curbing oil output, slowing cell overgrowth and dampening inflammation at the same time. The new review’s value is in showing those effects have replicated across independent experiments, which is why it grades CBD’s anti-inflammatory and sebostatic actions with moderate certainty.

The human data are weaker. One non-randomized clinical report described roughly a 40 percent drop in acne lesions after 12 weeks of topical CBD, along with less redness and oiliness. But the authors flag that the study lacked validated acne severity scales and patient-reported measures, which limits how much weight that figure can carry.

Why researchers still call it preliminary

The gap between “biologically plausible” and “clinically proven” is where this review does its real work. It rates clinical efficacy — actual reductions in lesions and redness in people — with low certainty, and direct antimicrobial activity against C. acnes lower still.

Three problems drag the human evidence down:

• Small samples. Most clinical studies were uncontrolled and enrolled few participants.
• No randomized trials. The randomized controlled trial is the standard for showing a treatment works, and the authors found only one randomized, double-blind study — which itself lacked acne-specific outcome measures.
• Confounded formulations. Most tested products combined CBD with other active ingredients such as salicylic acid, making it impossible to credit any improvement to CBD alone.

The authors are also precise about what they studied. They examined CBD-containing extracts from hemp flowers and leaves — not hemp seed oil, the cannabinoid-poor cold-pressed oil found in many “hemp” skincare products, which they excluded from the efficacy analysis. It is a distinction that routinely trips up shoppers reading ingredient labels, and one worth keeping in mind when weighing what CBD can realistically do for acne, aging or eczema.

What would move the needle

For now, the practical takeaway lands close to where dermatology research has been pointing for years: CBD looks best suited as an add-on for mild-to-moderate inflammatory acne, valued for its anti-inflammatory and oil-regulating effects rather than as a replacement for antibiotics or retinoids. Its short-term safety profile is reassuring — fewer than 10 percent of participants reported mild irritation, and no serious adverse events were recorded.

Getting the compound into the skin reliably remains a live obstacle. CBD is oily and poorly water-soluble, and it penetrates the skin unevenly, which is why researchers are testing nanoparticle carriers and other delivery systems to deliver a consistent dose — part of a broader push to solve CBD’s absorption problem.

What the field needs next, the authors argue, is unglamorous but specific: randomized trials comparing CBD on its own against placebo or standard care, standardized formulations that label the CBD concentration clearly, and validated ways to score acne severity. It is a familiar pattern in the wider science on CBD and skin health — strong laboratory mechanisms running well ahead of the clinical trials needed to confirm them. Until that work is done, the promise stays exactly that: promising, and unproven.

References:

^{1. Komane, Baatile and Kaye, Thobile, “CBD-Containing Hemp Extracts and Isolated CBD for Acne: A Systematic Review of Anti-Inflammatory Mechanisms, Clinical Signals and Sustainability” (2026). Molecules, 31(12), 2017. https://www.mdpi.com/1420-3049/31/12/2017}